Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Santhera gains exclusive option to Idorsia's vamorolone DMD candidate

Executive Summary

Santhera Pharmaceuticals AG acquired the option to exclusively sublicense Idorsia Pharmaceuticals Ltd.'s dissociative steroid vamorolone (VBP15) in all countries worldwide except Japan and South Korea.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register